ALB and neoplasm: One typical paradigm was the development of a biocompatible hybrid nanoparticle consisting of HSA and calcium phosphate (CaP) for Pt(IV) complex (Pt‐HSA/CaP) (Figure 15b).[49] HSA, a widely‐used drug carrier, possess the ability to protect Pt(IV) complexes from premature reduction before cellular uptake and enhance the targeting ability to malignant tumor tissues.[29] Under the weakly acidic environment, CaP can be degraded for the release of Pt‐HSA from the conjugate.